TY - JOUR
T1 - Serum-soluble interleukin-2 receptor (sIL-2R) is an extremely strong prognostic factor for patients with peripheral T-cell lymphoma, unspecified (PTCL-U)
AU - Kitagawa, Jun Ichi
AU - Hara, Takeshi
AU - Tsurumi, Hisashi
AU - Goto, Naoe
AU - Kanemura, Nobuhiro
AU - Yoshikawa, Takeshi
AU - Kasahara, Senji
AU - Yamada, Toshiki
AU - Sawada, Michio
AU - Takahashi, Takeshi
AU - Shimizu, Masahito
AU - Takami, Tsuyoshi
AU - Moriwaki, Hisataka
PY - 2009/1
Y1 - 2009/1
N2 - Purpose: The aim of this study was to assess the prognostic factors of peripheral T-cell lymphoma, unspecified (PTCL-U). Patients and methods: We retrospectively analyzed 30 cases fulfilling the criteria of PTCL-U defined by the World Health Organization classification. The patients were treated with 6-8 cycles of a CHOP or THP (pirarubicin)-COP regimen. Results: A high serum sIL-2R level (≥2,000 U/ml) at onset was associated with a low complete remission rate. Patients with high sIL-2R had significantly lower survival rates (5 year, 15.1%) than those with low sIL-2R (<2,000 U/ml) (100%) (P < 0.005). Factors associated with worse overall survival in a univariate analysis were high sIL-2R (P < 0.005), high age (>60 years) (P < 0.05), poor performance status (P < 0.01) and poor international prognostic index (P < 0.05). No correlation was observed between sIL-2R and other markers. Multivariate analysis showed that only sIL-2R was a prognostic factor for overall survival (P < 0.01). Conclusion: The results suggest that a high serum sIL-2R level predicts a poor prognosis in PTCL-U.
AB - Purpose: The aim of this study was to assess the prognostic factors of peripheral T-cell lymphoma, unspecified (PTCL-U). Patients and methods: We retrospectively analyzed 30 cases fulfilling the criteria of PTCL-U defined by the World Health Organization classification. The patients were treated with 6-8 cycles of a CHOP or THP (pirarubicin)-COP regimen. Results: A high serum sIL-2R level (≥2,000 U/ml) at onset was associated with a low complete remission rate. Patients with high sIL-2R had significantly lower survival rates (5 year, 15.1%) than those with low sIL-2R (<2,000 U/ml) (100%) (P < 0.005). Factors associated with worse overall survival in a univariate analysis were high sIL-2R (P < 0.005), high age (>60 years) (P < 0.05), poor performance status (P < 0.01) and poor international prognostic index (P < 0.05). No correlation was observed between sIL-2R and other markers. Multivariate analysis showed that only sIL-2R was a prognostic factor for overall survival (P < 0.01). Conclusion: The results suggest that a high serum sIL-2R level predicts a poor prognosis in PTCL-U.
UR - http://www.scopus.com/inward/record.url?scp=56649124727&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=56649124727&partnerID=8YFLogxK
U2 - 10.1007/s00432-008-0440-0
DO - 10.1007/s00432-008-0440-0
M3 - Article
C2 - 18592269
AN - SCOPUS:56649124727
SN - 0171-5216
VL - 135
SP - 53
EP - 59
JO - Journal of Cancer Research and Clinical Oncology
JF - Journal of Cancer Research and Clinical Oncology
IS - 1
ER -
